AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9288408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7906190 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 100 mg oral daily
Number of subjects: 67
Study 7906190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 7906190 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine and Placebo
Number of subjects: 67
Study 3307890 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine plus cimetidine 400 mg q.d.s. (21 patients)
Number of subjects: 120
Study 3307890 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine plus placebo (19 patients)
Number of subjects: 120
Study 31950895 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Neuromuscular Stabilization (DNS) training
Number of subjects: 34
Study 31950895 — intervention group
Group type: COMPARATOR
Intervention: Physical fitness (PF) training
Number of subjects: 34
Study 30497638 — intervention group
Group type: EXPERIMENTAL
Intervention: Food served in FCCHs
Number of subjects: 166
Study 30497638 — intervention group
Group type: EXPERIMENTAL
Intervention: Food consumed by children
Number of subjects: 166
Study 30497638 — intervention group
Group type: EXPERIMENTAL
Intervention: Food served
Number of subjects: 166
Study 28692641 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin clavulanate (oral) for 7 days
Number of subjects: 187
Study 28692641 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 187
Study 25602580 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 0
Study 25602580 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 23430708 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling plus nicotine replacement treatment (NRT)
Number of subjects: 209
Study 23430708 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based Internet smoking treatment plus NRT
Number of subjects: 209
Study 23430708 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help plus NRT
Number of subjects: 209
Study 21958958 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (12 mg/kg single dose)
Number of subjects: 97
Study 21958958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 21958958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen lysine salt (40 mg, open-label)
Number of subjects: 97
Study 18436083 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 842
Study 18436083 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (adjusted for proteinuria)
Number of subjects: 842
Study 18436083 — intervention group
Group type: COMPARATOR
Intervention: Randomized treatment group (blood pressure goal or antihypertensive drug)
Number of subjects: 842
Study 16611714 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contrast-enhanced computerized tomography (CT) scan
Number of subjects: 221
Study 16611714 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy aspirin ingestion
Number of subjects: 221
Study 16611714 — intervention group
Group type: EXPERIMENTAL
Intervention: Total analgesic ingestion > or =0.3 kg/yr
Number of subjects: 221
Study 16611714 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contrast-enhanced CT scan
Number of subjects: 221
Study 12893983 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg sibutramine daily for 54 weeks
Number of subjects: 111
Study 12893983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 12893983 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg sibutramine vs. placebo in CC genotype carriers
Number of subjects: 111
Study 11113039 — intervention group
Group type: EXPERIMENTAL
Intervention: (192)Ir
Number of subjects: 70
Study 11113039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 8871138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg, n = 71)
Number of subjects: 219
Study 8871138 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (n = 73)
Number of subjects: 219
Study 8871138 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 75)
Number of subjects: 219
Study 1735852 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf Neonatal)
Number of subjects: 41
Study 1735852 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 41
Study 6131624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg intravenously
Number of subjects: 100
Study 6131624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg orally
Number of subjects: 100
Study 6131624 — intervention group
Group type: COMPARATOR
Intervention: Magnesium trisilicate (control group)
Number of subjects: 100
Study 31353364 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T‐VEC) plus ipilimumab
Number of subjects: 198
Study 31353364 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 198
Study 29467053 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer with nutrition behaviour change communication (BCC)
Number of subjects: 4840
Study 27351678 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue
Number of subjects: 26
Study 27351678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 24135389 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 371
Study 24135389 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 371
Study 24135389 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 371
Study 24135389 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Rosiglitazone
Number of subjects: 371
Study 21227460 — intervention group
Group type: EXPERIMENTAL
Intervention: L-D (use of laparoscopic instruments with direct vision)
Number of subjects: 36
Study 21227460 — intervention group
Group type: COMPARATOR
Intervention: C-V (use of conventional instruments with indirect vision via a video monitor)
Number of subjects: 36
Study 21227460 — intervention group
Group type: COMPARATOR
Intervention: L-V (standard laparoscopic suturing and knot tying)
Number of subjects: 36
Study 21227460 — intervention group
Group type: EXPERIMENTAL
Intervention: HUESAD assessment
Number of subjects: 36
Study 20117252 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral furosemide (40mg)
Number of subjects: 14
Study 20117252 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide + oral volume replacement (F+R)
Number of subjects: 14
Study 20117252 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 14
Study 20117252 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide and F+R
Number of subjects: 14
Study 17295570 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretive group therapy
Number of subjects: 110
Study 17295570 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive group therapy
Number of subjects: 110
Study 15780739 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose (40 microg) of recombinant hepatitis B vaccine
Number of subjects: 210
Study 15780739 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (20 microg) of recombinant hepatitis B vaccine
Number of subjects: 210
Study 15780739 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose (40 microg) for patients with CD4 cell counts > or = 350 cells/mm3
Number of subjects: 210
Study 15780739 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (20 microg) for patients with CD4 cell counts > or = 350 cells/mm3
Number of subjects: 210
Study 15780739 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose (40 microg) for patients with CD4 cell counts < 350 cells/mm3
Number of subjects: 210
Study 15780739 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (20 microg) for patients with CD4 cell counts < 350 cells/mm3
Number of subjects: 210
Study 15780739 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose (40 microg) for patients with HIV viral load < 10,000 copies/mL
Number of subjects: 210
Study 15780739 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (20 microg) for patients with HIV viral load < 10,000 copies/mL
Number of subjects: 210
Study 15780739 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose (40 microg) for patients with HIV viral load > or = 10,000 copies/mL
Number of subjects: 210
Study 15780739 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (20 microg) for patients with HIV viral load > or = 10,000 copies/mL
Number of subjects: 210
Study 11919486 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP plus zidovudine (twice daily for 1 week)
Number of subjects: 800
Study 11919486 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose NVP alone
Number of subjects: 800
Study 11919486 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated infants born to HIV-uninfected women)
Number of subjects: 800
Study 10413343 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stimuli generated by alternating rotations in the horizontal plane of the seat of the chair
Number of subjects: 60
Study 10413343 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 60
Study 7785480 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic drinking
Number of subjects: 94
Study 7785480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sporadic drinking
Number of subjects: 94
Study 7785480 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady drinking
Number of subjects: 94
Study 7785480 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking
Number of subjects: 94
Study 7785480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment drinking pattern
Number of subjects: 94
Study 2078960 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 78
Study 2078960 — intervention group
Group type: COMPARATOR
Intervention: BSS
Number of subjects: 78
Study 7438350 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpericardiotomy syndrome (PPS)
Number of subjects: 400
Study 7438350 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiheart antibody (AHA)
Number of subjects: 400
Study 7438350 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral antibody (AVA)
Number of subjects: 400
Study 7438350 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral response to viral infections
Number of subjects: 400
Study 7438350 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral prevalence
Number of subjects: 400
Study 7438350 — intervention group
Group type: COMPARATOR
Intervention: Negative AHA
Number of subjects: 400
Study 30391343 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 1342
Study 30391343 — intervention group
Group type: COMPARATOR
Intervention: Control group (substance-free dormitory floors)
Number of subjects: 1342
Study 28504921 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen Activator Inhibitor-1 (PAI-1)
Number of subjects: 51
Study 28504921 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeostatic model assessment of insulin resistance
Number of subjects: 51
Study 28504921 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum triglycerides
Number of subjects: 51
Study 28504921 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardial fat
Number of subjects: 51
Study 25553747 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Intervention for Improving Occupational Performance (FI-OP) program
Number of subjects: 37
Study 25553747 — intervention group
Group type: COMPARATOR
Intervention: Playroom program
Number of subjects: 37
Study 23552336 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (12 sessions for 6 weeks)
Number of subjects: 22
Study 23552336 — intervention group
Group type: COMPARATOR
Intervention: Control group (generic exercise advice leaflet)
Number of subjects: 22
Study 20978279 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril
Number of subjects: 339
Study 20978279 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 339
Study 20978279 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril and losartan
Number of subjects: 339
Study 20978279 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 339
Study 19446890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg daily, p.o.)
Number of subjects: 21
Study 19446890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 19446890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 21
Study 17254831 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine uptake among students with younger, male, or not literate family heads.
Number of subjects: 0
Study 17254831 — intervention group
Group type: COMPARATOR
Intervention: Vaccine uptake among students from households with higher per-capita income.
Number of subjects: 0
Study 17254831 — intervention group
Group type: EXPERIMENTAL
Intervention: Residency south of the river or further from a hospital/polyclinic.
Number of subjects: 0
Study 17254831 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger students compared to older students in high- or low-risk areas.
Number of subjects: 0
Study 15658548 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrum osteomag (2 tablets daily for 12 months)
Number of subjects: 334
Study 15658548 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1500 mg)
Number of subjects: 334
Study 15658548 — intervention group
Group type: COMPARATOR
Intervention: Control group (only observation)
Number of subjects: 334
Study 11293926 — intervention group
Group type: EXPERIMENTAL
Intervention: Orocal D3 (500 mg calcium and 400 IU vitamin D3) taken in two doses at 6-hour intervals
Number of subjects: 12
Study 11293926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cacit vitamin D3 (1000 mg calcium and 880 IU vitamin D3) taken as a single morning dose
Number of subjects: 12
Study 11293926 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplements)
Number of subjects: 12
Study 9527329 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mm incision
Number of subjects: 197
Study 9527329 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm incision
Number of subjects: 197
Study 8196849 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam FDDF 20 mg/day
Number of subjects: 61
Study 8196849 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 1000 mg/day
Number of subjects: 61
Study 2853518 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% cyclopentolate
Number of subjects: 16
Study 2853518 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% tropicamide
Number of subjects: 16
Study 2853518 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol eye drops
Number of subjects: 16
Study 2853518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2853518 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% timolol
Number of subjects: 16
Study 2853518 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical X
Number of subjects: 16
Study 28943533 — intervention group
Group type: EXPERIMENTAL
Intervention: ST segment re-elevation after PPCI
Number of subjects: 662
Study 27457969 — intervention group
Group type: EXPERIMENTAL
Intervention: Food selection training game 'Happy goat says' with inhibition manipulation
Number of subjects: 20
Study 27457969 — intervention group
Group type: EXPERIMENTAL
Intervention: Food selection training game 'Happy goat says' with impulsivity manipulation
Number of subjects: 20
Study 27457969 — intervention group
Group type: EXPERIMENTAL
Intervention: Food selection training game 'Happy goat says' with control manipulation
Number of subjects: 20
Study 27457969 — intervention group
Group type: COMPARATOR
Intervention: Control group playing Lego blocks
Number of subjects: 20
Study 24858916 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 103
Study 24858916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 22461276 — intervention group
Group type: EXPERIMENTAL
Intervention: Noveon laser treatment for onychomycosis
Number of subjects: 0
Study 20978719 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgambond Plus
Number of subjects: 36
Study 20978719 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose
Number of subjects: 36
Study 20978719 — intervention group
Group type: COMPARATOR
Intervention: Copal varnish
Number of subjects: 36
Study 18843441 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-hitch throw on suture material
Number of subjects: 2160
Study 18843441 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of an extra throw in 2 x 1 x 1, 2 x 2, and 2 x 2 x 1 knots
Number of subjects: 2160
Study 18843441 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-throw knot configurations
Number of subjects: 2160
Study 18843441 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 2 knots
Number of subjects: 2160
Study 16491148 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorganic bovine bone graft plus 10% collagen (BO)
Number of subjects: 20
Study 16491148 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorganic bovine bone graft plus 10% collagen with bioresorbable collagen barrier (BO/BG)
Number of subjects: 20
Study 16491148 — intervention group
Group type: COMPARATOR
Intervention: Comparison between BO and BO/BG
Number of subjects: 20
Study 12960596 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic mapping with labelled colloid and patent blue violet
Number of subjects: 16
Study 10726910 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate treatment (16 weeks)
Number of subjects: 342
Study 10726910 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate treatment (8 weeks)
Number of subjects: 342
Study 9292071 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical all‐trans retinoic acid (RA)
Number of subjects: 0
Study 9292071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate (SLS)
Number of subjects: 0
Study 9292071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem application of RA and SLS
Number of subjects: 0
Study 9292071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate (SLS) followed by topical all‐trans retinoic acid (RA)
Number of subjects: 0
Study 1606395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal N-acetylcysteine (5% N-acetylcysteine administered every 4 hours for one week)
Number of subjects: 10
Study 1606395 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (administered every 4 hours for one week)
Number of subjects: 10
Study 3860334 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (classroom preventive dentistry presentations)
Number of subjects: 854
Study 3860334 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 854
Study 29992600 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week home-based self-help psychoeducation program
Number of subjects: 129
Study 29992600 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study 27503288 — intervention group
Group type: EXPERIMENTAL
Intervention: rs117026326 on GTF2I
Number of subjects: 242
Study 27503288 — intervention group
Group type: EXPERIMENTAL
Intervention: rs13079920 on RBMS3
Number of subjects: 242
Study 27503288 — intervention group
Group type: EXPERIMENTAL
Intervention: rs13072846
Number of subjects: 242
Study 24183460 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 cycles of FEC100
Number of subjects: 837
Study 24183460 — intervention group
Group type: COMPARATOR
Intervention: 4 FEC100 followed by 4 Taxol (4FEC100-4T)
Number of subjects: 837
Study 23136273 — intervention group
Group type: EXPERIMENTAL
Intervention: AAQ (artesunate amodiaquine)
Number of subjects: 0
Study 23136273 — intervention group
Group type: EXPERIMENTAL
Intervention: AAQ + AMX (artesunate amodiaquine with amoxicillin)
Number of subjects: 0
Study 23136273 — intervention group
Group type: EXPERIMENTAL
Intervention: AAQ
Number of subjects: 0
Study 23136273 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study 19935071 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25%
Number of subjects: 30
Study 19935071 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with 1 microg kg(‐1) dexmedetomidine
Number of subjects: 30
Study 18550508 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFCA)
Number of subjects: 96
Study 18550508 — intervention group
Group type: EXPERIMENTAL
Intervention: High homocysteine levels
Number of subjects: 96
Study 18550508 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine levels
Number of subjects: 96
Study 16117995 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan treatment
Number of subjects: 603
Study 12861400 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal defect suturing (Group I)
Number of subjects: 10
Study 12861400 — intervention group
Group type: COMPARATOR
Intervention: No mucosal defect suturing (Group II)
Number of subjects: 10
Study 10235025 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with stem cell support (induction with cyclophosphamide and taxol, followed by three high dose cycles of carboplatin, taxol, etoposide, and melphalane)
Number of subjects: 49
Study 10235025 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (as per AGO-Ovar-5-study)
Number of subjects: 49
Study 9112171 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/ml MMC
Number of subjects: 29
Study 9112171 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/ml MMC
Number of subjects: 29
Study 9112171 — intervention group
Group type: COMPARATOR
Intervention: Control (no MMC)
Number of subjects: 29
Study 9112171 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1, 2, and 3)
Number of subjects: 29
Study 1989739 — intervention group
Group type: EXPERIMENTAL
Intervention: Hose method of oxygen supplementation
Number of subjects: 66
Study 1989739 — intervention group
Group type: COMPARATOR
Intervention: Face mask oxygen supplementation
Number of subjects: 66
Study 6348714 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 25 mg
Number of subjects: 152